On March 3, 2022 VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, reported that management will participate in a fireside chat at the 34th Annual Roth Conference being held on March 13 – 15, 2022 as well as at the 32nd Annual Oppenheimer Healthcare Conference taking place on March 15 – 17, 2022 (Press release, VBL Therapeutics, MAR 3, 2022, View Source [SID1234609443]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

34th Annual Roth Conference
Format: Fireside Chat
Date: Monday, March 14, 2022
Time: 9:30-9:55 AM (PT)
Fireside Chat Webcast Link
Pre-Conference Webinar Link

32nd Annual Oppenheimer Healthcare Conference
Format: Fireside Chat
Date: Wednesday, March 16, 2022
Time: 8:40-9:10 AM (ET)
Fireside Chat Webcast Link

A link to the webcasts of both fireside chats and the Roth pre-conference webinar will also be available on the Events and Presentations page of the Investor Relations section on the Company’s website at www.vblrx.com.